At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
SAAVI DNA-C2 vaccine +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Dec 17, 2007·Updated Oct 14, 2021
In Brief
A Phase 1 clinical trial evaluating SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine, and 1 other intervention for HIV Infections. Completed, enrolled 48 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with an experimental modified vaccinia HIV vaccine (MVA) in HIV uninfected adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesSouth Africa, United States
CollaboratorsHIV Vaccine Trials Network
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2007
Enrollment StartNov 2008
Primary CompletionOct 2010
Study CompletionJan 2013
TodayJul 2026
First PostedDec 17, 2007
Enrollment StartNov 1, 2008
Primary CompletionOct 1, 2010
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.5 years ago
Interventions
SAAVI DNA-C2 vaccinebiological
DNA vaccine
SAAVI MVA-C vaccinebiological
Boost vaccine
Placebobiological
Placebo vaccine